Skip to main content
SpringerLink
Log in

Therapie des Asthma bronchiale

Wie gut sind wir wirklich?

Treatment of bronchial asthma

How good are we really?

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Asthma bronchiale ist eine chronisch entzündliche Erkrankung, die mit Atemwegsobstruktion und Hyperreagibilität einhergeht. Weltweit ist eine steigende Prävalenz der Erkrankung nachzuweisen. Trotz Fortschritten in der medikamentösen Therapie und nationaler und internationaler Leitlinien ist ein Teil der Patienten nicht adäquat kontrolliert. Dies betrifft auch Patienten mit gering- und mittelgradiger persistierender Erkrankung. Im folgenden Beitrag fassen wir die Grundlagen der medikamentösen Behandlung von Patienten mit gering- und mittelgradig persistierender Erkrankung zusammen.

Abstract

Asthma is a chronic inflammatory disorder associated with airflow obstruction and airway hyperreactivity. An increase in prevalence is detectable worldwide. Despite advances in the medical treatment and international and national asthma management guidelines, some patients are not controlled adequately. This also includes patients with mild and moderate persistent disease. In the following review we summarize the treatment of patients with mild to moderate persistent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abramson MJ, Puy RM, Weiner JM (2003) Allergen immunotherapy for asthma. Cochrane Database Syst Rev: CD001186

    Google Scholar 

  2. Bateman ED, Boushey HA, Bousquet J et al. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170: 836–844

    Article  PubMed  Google Scholar 

  3. Berry MA, Hargadon B, Shelley M et al. (2006) Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354: 697–708

    Article  PubMed  CAS  Google Scholar 

  4. Bisgaard H, Hermansen MN, Loland L et al. (2006) Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354: 1998–2005

    Article  PubMed  CAS  Google Scholar 

  5. Boushey HA, Sorkness CA, King TS et al. (2005) Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 352:1519–28.

    Article  PubMed  CAS  Google Scholar 

  6. Buhl R, Beeh KM (2003) Specific immunotherapy for allergic asthma?. Pneumologie 57: 69–70

    Article  PubMed  CAS  Google Scholar 

  7. Buhl R, Berdel D, Criee CP et al. (2006) Guidelines for diagnosis and treatment of asthma patients. Pneumologie 60: 139–177

    Article  PubMed  CAS  Google Scholar 

  8. Deykin A, Wechsler ME, Boushey HA et al. (2007) Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 175: 228–234

    Article  PubMed  CAS  Google Scholar 

  9. Ducharme FM (2002) Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 324: 1545

    Article  PubMed  CAS  Google Scholar 

  10. Ducharme FM, Hicks GC (2002) Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev: CD002314

    Google Scholar 

  11. Erin EM, Leaker BR, Nicholson GC et al. (2006) The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174: 753–762

    Article  PubMed  CAS  Google Scholar 

  12. Evans DJ, Taylor DA, Zetterstrom O et al. (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337: 1412–1418

    Article  PubMed  CAS  Google Scholar 

  13. FitzGerald JM, Becker A, Sears MR et al. (2004) Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59: 550–556

    Article  PubMed  CAS  Google Scholar 

  14. Guilbert TW, Morgan WJ, Zeiger RS et al. (2006) Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354: 1985–1997

    Article  PubMed  CAS  Google Scholar 

  15. Haahtela T, Jarvinen M, Kava T et al. (1994) Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331: 700–705

    Article  PubMed  CAS  Google Scholar 

  16. Harrison TW, Oborne J, Newton S, Tattersfield AE (2004) Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363: 271–275

    Article  PubMed  CAS  Google Scholar 

  17. Holgate ST, Price D, Valovirta E (2006) Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med 6 (Suppl 1): S2–S2

    Article  PubMed  Google Scholar 

  18. Ind PW, Villasante C, Shiner RJ et al. (2002) Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. Eur Respir J 20: 859–866

    Article  PubMed  CAS  Google Scholar 

  19. National Heart LaBI, National Institutes of Health B (2007) Global Initiative for Asthma (GINA). http://www ginaasthma com (updated December 2006)

  20. Nelson HS, Busse WW, Kerwin E et al. (2000) Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106: 1088–1095

    Article  PubMed  CAS  Google Scholar 

  21. Nelson HS, Weiss ST, Bleecker ER et al. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129: 15–26

    Article  PubMed  CAS  Google Scholar 

  22. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. (2001) Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164: 1392–1397

    Google Scholar 

  23. O’Byrne PM, Bisgaard H, Godard PP et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171: 129–136

    Google Scholar 

  24. Palmqvist M, Ibsen T, Mellen A, Lotvall J (1999) Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 160: 244–249

    PubMed  CAS  Google Scholar 

  25. Papi A, Canonica GW, Maestrelli P et al. (2007) Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356: 2040–2052

    Article  PubMed  CAS  Google Scholar 

  26. Pauwels RA, Pedersen S, Busse WW et al. (2003) Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361: 1071–1076

    Article  PubMed  CAS  Google Scholar 

  27. Pauwels RA, Lofdahl CG, Postma DS et al. (1997) Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. N Engl J Med 337: 1405–1411

    Article  PubMed  CAS  Google Scholar 

  28. Rabe KF, Atienza T, Magyar P et al. (2006) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368: 744–753

    Article  PubMed  CAS  Google Scholar 

  29. Rabe KF, Pizzichini E, Stallberg B et al. (2006) Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 129: 246–256

    Article  PubMed  CAS  Google Scholar 

  30. Scicchitano R, Aalbers R, Ukena D et al. (2004) Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20: 1403–1418

    Article  PubMed  CAS  Google Scholar 

  31. Sears MR, Taylor DR, Print CG et al. (1990) Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336: 1391–1396

    Article  PubMed  CAS  Google Scholar 

  32. Stoloff SW, Stempel DA, Meyer J et al. (2004) Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 113: 245–251

    Article  PubMed  Google Scholar 

  33. Szefler SJ, Martin RJ, King TS et al. (2002) Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109: 410–418

    Article  PubMed  CAS  Google Scholar 

  34. The American Lung Association Asthma Clinical Research Center (2007) Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 356: 2027–2039

    Article  Google Scholar 

  35. The Childhood Asthma Management Program Research Group (2000) Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343: 1054–1063

    Article  Google Scholar 

  36. Walker S, Monteil M, Phelan K et al. (2006) Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 19; CD003559

  37. Zeiger RS, Bird SR, Kaplan MS et al. (2005) Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 118: 649–657

    Article  PubMed  CAS  Google Scholar 

  38. Zetterstrom O, Buhl R, Mellem H et al. (2001) Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18: 262–268

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Herr Dr. Taube ist als Referent für die Firmen Asche Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline und Novartis tätig. Herr Prof. Dr. R. Buhl ist als Referent und/oder Berater für Asche Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck (Darmstadt), Novartis, Nycomed und Talecris tätig.

Author information

Authors and Affiliations

  1. Schwerpunkt Pneumologie, III. Medizinische Klinik, Johannes Gutenberg Universität Mainz, Langenbeckstraße 1, 55101, Mainz, Deutschland

    C. Taube & R. Buhl

Authors
  1. C. Taube
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Buhl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Taube.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taube, C., Buhl, R. Therapie des Asthma bronchiale. Pneumologe 5, 24–31 (2008). https://doi.org/10.1007/s10405-007-0183-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-007-0183-7

Schlüsselwörter

Keywords

Search

Navigation